Iqvia Holdings Inc (NYSE:IQV) Holdings Lifted by McGuire Investment Group LLC

McGuire Investment Group LLC increased its position in Iqvia Holdings Inc (NYSE:IQV) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 85,133 shares of the medical research company’s stock after buying an additional 1,514 shares during the quarter. Iqvia comprises about 4.3% of McGuire Investment Group LLC’s investment portfolio, making the stock its 2nd biggest position. McGuire Investment Group LLC’s holdings in Iqvia were worth $13,698,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Iqvia by 7.0% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,251 shares of the medical research company’s stock valued at $1,331,000 after acquiring an additional 608 shares in the last quarter. GYL Financial Synergies LLC acquired a new stake in shares of Iqvia during the first quarter valued at about $4,349,000. Globeflex Capital L P grew its stake in shares of Iqvia by 96.6% during the first quarter. Globeflex Capital L P now owns 10,784 shares of the medical research company’s stock valued at $1,551,000 after acquiring an additional 5,299 shares in the last quarter. Meridian Wealth Advisors LLC grew its stake in shares of Iqvia by 13.0% during the first quarter. Meridian Wealth Advisors LLC now owns 4,197 shares of the medical research company’s stock valued at $604,000 after acquiring an additional 482 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Iqvia by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock valued at $247,087,000 after acquiring an additional 164,811 shares in the last quarter. 90.38% of the stock is currently owned by institutional investors.

In related news, insider Ari Bousbib sold 96,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $160.00, for a total transaction of $15,360,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kevin C. Knightly sold 6,945 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $158.53, for a total value of $1,100,990.85. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 198,945 shares of company stock worth $30,860,991. Corporate insiders own 6.00% of the company’s stock.

IQV has been the subject of several recent analyst reports. Wells Fargo & Co raised their target price on Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Credit Suisse Group lifted their price target on Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. William Blair reiterated an “outperform” rating on shares of Iqvia in a research note on Wednesday, June 19th. SunTrust Banks lifted their price target on Iqvia from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Leerink Swann started coverage on Iqvia in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 price target for the company. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $161.13.

Shares of NYSE IQV opened at $151.80 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 1.72. The stock has a 50-day simple moving average of $157.55. Iqvia Holdings Inc has a 52-week low of $104.90 and a 52-week high of $164.13. The company has a market capitalization of $30.77 billion, a PE ratio of 29.65, a P/E/G ratio of 1.91 and a beta of 0.88.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.01. The company had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.29 earnings per share. On average, research analysts anticipate that Iqvia Holdings Inc will post 5.86 earnings per share for the current year.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also: Why do companies pay special dividends?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.